Based on these results, we do not expect that the proposed approach in the current investigation to pancreatic tumor-targeting can increase the adverse side effects compared to similar liposomal formulations targeted to tumors by the LHRH peptide. Here, GNRH1 is linked to pancreatic neoplasm.